Quick Answer
Bicara Therapeutics Inc. reported Operating Income Loss of -$155.60 million for the year ending 2025.
- Bicara Therapeutics Inc. showed a decrease of -88.9% in Operating Income Loss from 2024 to 2025.
- This data is from Bicara Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2023: -$9.53 million | Q1 2024: -$15.37 million | Q2 2024: -$19.75 million | Q3 2024: -$20.63 million | Q1 2025: -$41.79 million | Q2 2025: -$32.02 million | Q3 2025: -$40.68 million.
- Over the full 3 years of available data (2023 to 2025), Bicara Therapeutics Inc.'s Operating Income Loss has declined by 290.1%.
- Historical annual values: Fiscal year 2025: -$155.60 million | Fiscal year 2024: -$82.39 million | Fiscal year 2023: -$39.89 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: